NFE2L2 and non-small cell lung carcinoma: For instance, sapanisertib, a TORC1/2 inhibitor, has shown enhanced therapeutic efficacy and extended progression-free survival in NSCLC models and phase II clinical trial populations characterized by Nrf2 activation 170.